Twist Bioscience (NASDAQ:TWST) Announces Earnings Results

Twist Bioscience (NASDAQ:TWST) posted its earnings results on Monday. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09, Zacks reports. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. Twist Bioscience updated its Q2 2025 guidance to EPS and its FY 2025 guidance to EPS.

Twist Bioscience Stock Performance

TWST stock opened at $52.37 on Monday. Twist Bioscience has a 52-week low of $27.41 and a 52-week high of $60.90. The company’s 50 day simple moving average is $48.39 and its 200-day simple moving average is $46.23.

Insider Activity

In other news, CAO Robert F. Werner sold 1,448 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the sale, the chief accounting officer now owns 45,620 shares in the company, valued at $2,034,652. The trade was a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Chess sold 3,600 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $47.26, for a total transaction of $170,136.00. Following the completion of the transaction, the director now owns 21,641 shares in the company, valued at approximately $1,022,753.66. This represents a 14.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 80,407 shares of company stock worth $3,757,443 over the last 90 days. 3.01% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TWST. Scotiabank upped their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Barclays reduced their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Robert W. Baird upped their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 19th. Wolfe Research began coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Finally, TD Cowen reaffirmed a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.